Study finds UGN-102 well-tolerated in patients with NMIBC


In this video, William C. Huang, MD, discusses the findings and takeaways of a recent phase 2b trial published in the Journal of Urology, which investigates the agent UGN-102 as a treatment for patients with non–muscle-invasive bladder cancer (NMIBC). Huang is a professor in the departments of urology and radiology at the New York University Grossman School of Medicine and the chief of urology at Tisch Hospital, New York City.

Related Videos
Abstract blur luxury hospital corridor | Image Credit: @ zephyr_p - @ zephyr_p -
Related Content
© 2024 MJH Life Sciences

All rights reserved.